TRVN vs. APGN, CMRA, CVKD, VRPX, CYCN, CANF, SBFM, BWV, ITRM, and GTBP
Should you be buying Trevena stock or one of its competitors? The main competitors of Trevena include Apexigen (APGN), Comera Life Sciences (CMRA), Cadrenal Therapeutics (CVKD), Virpax Pharmaceuticals (VRPX), Cyclerion Therapeutics (CYCN), Can-Fite BioPharma (CANF), Sunshine Biopharma (SBFM), Blue Water Biotech (BWV), Iterum Therapeutics (ITRM), and GT Biopharma (GTBP). These companies are all part of the "pharmaceutical preparations" industry.
Trevena vs.
Apexigen (NASDAQ:APGN) and Trevena (NASDAQ:TRVN) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, analyst recommendations, valuation, dividends, risk, profitability, media sentiment and community ranking.
Trevena received 610 more outperform votes than Apexigen when rated by MarketBeat users. However, 80.00% of users gave Apexigen an outperform vote while only 74.15% of users gave Trevena an outperform vote.
Apexigen currently has a consensus price target of $11.50, suggesting a potential upside of 2,886.24%. Trevena has a consensus price target of $5.50, suggesting a potential upside of 727.69%. Given Trevena's higher possible upside, research analysts clearly believe Apexigen is more favorable than Trevena.
Apexigen has a beta of 3.6, meaning that its share price is 260% more volatile than the S&P 500. Comparatively, Trevena has a beta of 1.91, meaning that its share price is 91% more volatile than the S&P 500.
Apexigen has higher earnings, but lower revenue than Trevena.
Apexigen's return on equity of -265.73% beat Trevena's return on equity.
In the previous week, Trevena's average media sentiment score of 0.00 equaled Apexigen'saverage media sentiment score.
13.6% of Apexigen shares are owned by institutional investors. Comparatively, 5.0% of Trevena shares are owned by institutional investors. 19.2% of Apexigen shares are owned by insiders. Comparatively, 3.3% of Trevena shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Summary
Apexigen beats Trevena on 6 of the 11 factors compared between the two stocks.
Get Trevena News Delivered to You Automatically
Sign up to receive the latest news and ratings for TRVN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding TRVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Related Companies and Tools